Background/Objectives: This study explores an oral immunisation strategy for HIV, using antibodies targeting the conserved gp120 254–274 region to stimulate immune responses without direct antigen exposure. Methods: Antibodies were administered via the gastrointestinal tract in feline models. The goal was to assess mucosal immune engagement and the induction of adaptive immunity through host recognition of antibody idiotypes. Immune responses were evaluated through endogenous antibody production and functional binding inhibition assays. Results: The orally delivered antibodies successfully triggered secondary immune responses, leading to the production of host antibodies that inhibited HIV gp120 binding. This demonstrated effective immune activation and functional protection. Conclusions: Oral administration of anti-gp120 antibodies can stimulate mucosal and systemic immunity, offering a novel and practical platform for HIV immunotherapy and a potential alternative to conventional vaccines.
Glutamatergic pathway abnormalities are increasingly recognised as central to various neuropsychiatric disorders, including autoimmune encephalitis, schizophrenia, and epilepsy, where autoantibodies targeting NMDA, AMPA, and GluR3 receptors are frequently implicated. In systemic lupus erythematosus (SLE), these autoantibodies, along with pro-inflammatory cytokines, are linked to neurocognitive impairments and mood disturbances. Elevated cytokine levels similarly contribute to the pathophysiology of epilepsy and other neurological conditions. Immunotherapies such as intravenous immunoglobulin (IVIG) have shown efficacy in mitigating some autoimmune neurological symptoms, though they offer limited benefit in disorders like amyotrophic lateral sclerosis and autism. Moreover, disruption of the blood-brain barrier—as observed in diseases such as multiple sclerosis and Guillain-Barré syndrome—permits pathogenic immune elements to infiltrate the central nervous system, exacerbating neuroinflammation. These insights highlight the urgent need for precise immunological screening and personalised treatment strategies to address immune-related neurological dysfunctions.
The Caribbean exhibits hyperendemic dengue transmission with near-universal adult seroprevalence in many territories, driven by sustained co-circulation of all four DENV serotypes and the domestic ecology of Aedes aegypti. Serosurveys report adult IgG rates as high as 93–100% in the French West Indies, Puerto Rico, and Jamaica, while children frequently acquire multitypic immunity before adolescence. High inapparent infection rates and population mobility complicate surveillance and mask true transmission intensity. These immunoepidemiological conditions elevate the risk of severe disease via antibody-dependent enhancement and challenge both acute diagnostics and vaccine policy. Effective control demands year-round integrated vector management, improved molecular and neutralization-based surveillance, pediatric-focused prevention strategies, and cautious deployment of balanced tetravalent vaccines informed by serotype-specific and genomic data.
Antibody-drug conjugates (ADCs) represent a novel and rapidly evolving class of targeted therapeutics that combine the high specificity of monoclonal antibodies (mAbs) with the potent cytotoxic effects of small-molecule drugs. These engineered molecules are designed to selectively deliver cytotoxic agents to specific cells, thereby reducing off-target toxicity and enhancing therapeutic efficacy. In oncology, ADCs have already demonstrated significant clinical success, particularly in the treatment of hematological malignancies and solid tumors. Agents such as trastuzumab emtansine and brentuximab vedotin exemplify how ADCs can effectively target cancer cells while limiting damage to healthy tissues. This review comprehensively explores key aspects of the use of ADCs in autoimmune disorders—an evolving field in immunotherapy.
Salmonella infections in poultry represent a significant threat to public health and contribute to substantial economic losses within the agricultural sector. In response to these challenges, this study explored an innovative dual control strategy integrating the use of indigenous plant-based bacterial attenuation with targeted immunotherapy using egg yolk-derived immunoglobulin Y (IgY) antibodies. Garlic (Allium sativum) and onion (Allium cepa) extracts were employed to attenuate virulent strains of Salmonella enterica, resulting in a notable reduction in bacterial viability during in vitro assays. Following oral vaccination with the attenuated strains, chickens mounted a robust immune response, characterised by the production of high titres of anti-Salmonella IgY antibodies, as measured by ELISA. Functional assays demonstrated that these antibodies possessed strong agglutination activity against homologous Salmonella strains, highlighting their utility in passive immunisation protocols. Safety assessments confirmed the vaccine’s non-pathogenic profile, while immunogenicity trials showed consistent antibody production across vaccinated flocks. This dual modality—combining natural antimicrobial agents with specific IgY-based immunotherapy—offers a sustainable, low-cost alternative to antibiotics, with the potential to reduce zoonotic transmission, enhance poultry welfare, and support antimicrobial stewardship in animal husbandry.
This systematic review and meta-analysis evaluates the evolution and scientific productivity of immunology in South America and the Caribbean from 2000 to 2025. Using PRISMA 2020 guidelines, 44 peer-reviewed studies were selected from indexed and regional databases. These studies reflect the thematic transition of immunology from infectious disease surveillance to personalised immunotherapies and systems biology. The meta-analysis confirmed exponential growth in publication trends (R² = 0.89) and thematic diversification. Contributions from both institutional centres and pioneering regional researchers were assessed. Heterogeneity (I² = 78%) among methodologies was reduced after sensitivity adjustment. The findings affirm that regional immunology is globally relevant and growing, though gaps remain in visibility, standardisation, and equity. Future directions include AI integration, vaccine equity, and immunogenomic mapping.